Renal cell carcinoma

Title Study Year Journal/Event
The PAZOREAL study: A non-interventional study to assess efficacy and safety of Pazopanib and everolimus in a real life settin; reflecting a changing mRCC treatment landscape.

Goebell P-J, Doehn C, Grüllich C, Grünwald V, Steiner T, Welslau M. Oncol Res Treat. 2016;39 (suppl.3)(P883):267.

PAZOREAL 2016 DGHO
The PAZOREAL Non-Interventional Study to Assess Effectiveness and Safety of Pazopanib and Everolimus in the Changing Metastatic Renal Cell Carcinoma Treatment Landscape.

Goebell P, Doehn C, Grüllich C, Steiner T, Ehneß R, Welslau M. Ann Oncol. 2016;27(suppl_6): 852P.

PAZOREAL 2016 ESMO
Survival of Patients With Advanced or Metastatic Renal Cell Carcinoma in Routine Practice Differs From That in Clinical Trials-Analyses From the German Clinical RCC Registry.

Marschner N, Staehler M, Müller L, Nusch A, Harde J, Koska M, et al. Clin Genitourin Cancer. 2016 Sep 8;

RCC 2016 Clin Genitourin Cancer
Adverse reactions in mRCC patients documented in routine practice by German office-based oncologists and uro-oncologists.

Marschner N, Müller L, Münch A, Blumenstengel K, Hutzschenreuter U, Busies S. J Oncol Pharm Pract. 2016 Feb 22.

RCC 2016 Journal of Oncology Pharmacy Practice
A Cross-Sectional Investigation of Fatigue, Mucositis, Hand-Foot Syndrome and Dysgeusia in Advanced Renal Cell Carcinoma Treatment: Final Results From the FAMOUS Study.

Goebell PJ, Müller L, Hurtz H-J, Koska M, Busies S, Marschner N. Clinical Genitourinary Cancer. 2016 Feb;14(1):63–8.

RCC 2016 Clinical Genitourinary Cancer
Survival data from patients with advanced or metastatic renal cell carcinoma in routine practice differs significantly from clinical trial data – Analyses from the German clinical RCC Registry.

Marschner N, Müller L, Staehler M, Nusch A, Münz M, Koska M, et al. Oncol Res Treat. 2015;38 (suppl.5)(V674):204.

RCC 2015 DGHO
Survival data from patients with advanced or metastatic renal cell carcinoma in routine practice differs significantly from clinical trial data – Analyses from the German clinical RCC Registry.

Goebell P, Müller L, Staehler M, Nusch A, Münz M, Koska M, et al. EAU (European Association of Urology). 2015;(Abstract 6).

RCC 2015 EAU
SWITCH: a randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) / sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC).

Weikersthal LF von, Goebell PJ, de Santis M de, Lerchenmüller C, Zimmermann U, Bos MMEM, et al. Oncol Res Treat. 2014;37 (suppl 5)(V28):5.

RCC-SWITCH 2014 DGHO
Interim analysis of a non-interventional study evaluating the quality of life in second-line treatment of metastatic renal cell carcinoma with everolimus (EVERPRO).

Bergmann L, Goebell P, Kloß S, Schirrmacher-Memel S, Warnack W, Kube U, et al. Oncol Res Treat. 2014;37 (suppl.5)(P282):89.

EVERPRO-NIS 2014 DGHO
Plasmaproteine zur Vorhersage des Zweitlinien-Therapieansprechens bei metastasierten Nierenzellkarzinomen.

Hölters S, Bergmann L, Grünwald V, Keilholz U, Ohlmann C, Staehler M, u. a. SWDGU (Mannheim). 2014;

MARC-2 2014 SWDGU
Plasmaproteine zur Vorhersage des Zweitlinien-Therapieansprechens bei metastasierten Nierenzellkarzinomen.

Hölters S, Bergmann L, Grünwald V, Keilholz U, Ohlmann C, Staehler M, u. a. Nierensymposium (Saarbrücken). 2014;

MARC-2 2014 Nierensymposium
Plasma proteins characterize second-line therapy response in progressive renal cell carcinoma.

Hölters S, Bergmann L, Grünwald V, Keilholz U, Ohlmann C, Staehler M, u. a. AACR (San Diego). 2014; 901

MARC-2 2014 AACR
Behandlungsrealität von Patienten mit metastasiertem Nierenzellkarzinom in Deutschland – Daten aus dem RCC-Register.

Eder E, Müller L, Hübner A, Koska M, Marschner N, Goebell P-J. Oral presentation at Gemeinsame Tagung BUV/OEGU. 2014;(FV17).

RCC 2014 BUV/OEGU
Behandlungsrealität von Patienten mit metastasiertem Nierenzellkarzinom in Deutschland – Daten aus dem RCC-Register.

Goebell P-J, Müller L, Hübner A, Lück A, Koska M, Marschner N. oral presentation at DGU. 2014;V07:674.

RCC 2014 DGU
Patienten mit Hirnmetastasen des fortgeschrittenen oder metastasierten Nierenzellkarzinoms – Daten aus dem klinischen RCC-Register.

Müller, L., Goebell, P.J., Reichert, D., Krieger, J.U., Jänicke M., Harde, J., Koska M., Marschner N. OncolResTreat 2014; 37(suppl.5)(P287)

RCC 2014 DGHO
Effectiveness of 1st-line treatment options in mRCC – a German RCC-Registry evaluation.

Goebell PJ, Müller L, Lück A, Overkamp F, Vogt M, Marschner N. J Clin Oncol 32, 2014 (suppl 4; abstr 429)

RCC 2014 GCS (ASCO)
Sequential treatment of advanced or metastatic renal cell carcinoma (mRCC) – What is effective? Data from the German RCC Registry.

Goebell PJ, Müller L, Lück A, Overkamp F, Vogt M, Marschner N. J Clin Oncol 32, 2014 (suppl 4; abstr 499)

RCC 2014 GCS (ASCO)
A cross-sectional investigation of fatigue in advanced renal cell carcinoma treatment: Results from the FAMOUS study.

Goebell P, Münch A, Müller L, Hurtz H-J, Koska M, Busies S, u. a. Urol Oncol. 2014;32(3):362-70.

RCC 2014 Urol Oncol
SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC).

Michel MS, Vervenne W, Santis M de, Weikersthal LF von, Goebell PJ, Lerchenmueller C, u. a. J Clin Oncol. 2014 ; 32(suppl 4; abstr 393).

RCC-Switch 2014 GCS (ASCO)
Prediction of second-line therapy response in metastatic renal cell carcinoma patients by blood plasma marker proteins.

Hölters S, Bergmann L, Grünwald V, Keilholz U, Ohlmann C, Staehler M, u. a. ESUR. 2013; P17

MARC-2 2013 ESUR (EAU)
The German mRCC Registry – aims and results after the first 1000 patients.

Goebell PJ, Müller L, Blumenstengel K, Hübner A, Lück A, Vogt M, u. a. 2013

RCC 2013 EAU
Body-Mass-Index und Überleben von Patienten mit fortgeschrittenem oder metastasiertem Nierenzellkarzinom: Daten aus dem Klinischen RCC-Register.

Müller L, Goebell PJ, von Verschuer U, Hurtz H-J, Franzem M, Vogt M, u. a. Onkologie. 2013;(V41).

RCC 2013 DGHO
Effectiveness of sequential treatment of advanced or metastatic renal cell carcinoma (mRCC). Outcome data from the clinical RCC Registry.

Goebell PJ, Müller L, Lück A, Overkamp F, Vogt M, Marschner N.Onkologie. 2013;(V40).

RCC 2013 DGHO
Body-mass-index and survival of patients with metastastic renal cell carcinoma: Data from the German prospective RCC Registry.

Müller L, Goebell P, Von Verschuer U, Hurtz H, Franzem M, Vogt M, u. a. 2013;(P 454).

RCC 2013 GCS (ASCO)
Sequential systemic treatments of patients with metastatic renal cell carcinoma in German oncology and onco-urology outpatient centers. Data from the clinical RCC Registry.

Müller L, Goebell P, Harich H, Vogt M, Marschner N. Onkologie. 2012;35 (Suppl.6)(V684):202.

RCC 2012 DGHO
How to further solidify data on systemic therapy in metastatic renal cell carcinoma (mRCC) in German mRCC registry on the treatment reality.

Goebell P, Müller L, Blumenstengel K, Hübner A, Lück A, Koska M, u. a. 2012;

RCC 2012 EAU
MARC-2: An open-label trial to characterize patients with metastatic renal cell carcinoma (mRCC) treated with everolimus after failure of the first VEGFR-TKI therapy.

Staehler M, Bergmann L, Grünwald V, Huschke T, Keilholz U, Ohlmann C, u. a. J Clin Oncol. 2012;30(suppl 5; abstr 467).

MARC-2 2012 GCS (ASCO)
MARC-2: An open label, single arm trial to characterize patients with metastatic renal cell carcinoma treated with everolimus after failure of the first VEGF-targeted therapy.

Staehler M, Bergmann L, Grünwald V, Keilholz U, Ohlmann C-H, Schaller F, u. a. J Cancer Res Clin Oncol. 2012;138(Suppl. 1, Abstract 0327):141–2.

MARC-2 2012 DKK
Real-life treatment of patients with advanced or metastatic renal cell carcinoma in German oncology and urology outpatient centers (RCC-Registry).

Müller L, Goebell PJ, Blumenstengel K, Lueck A, Koska M, Marschner N. J Clin Oncol. 2011;29 (suppl 7)(Abstract 367).

RCC 2011 GCS (ASCO)
Die Behandlungsrealität von Patienten mit metastasiertem Nierenzellkarzinom in Deutschland – Update aus dem RCC-Register.

Goebell PJ, Müller L, Blumenstengel K, Hübner A, Lück A, Koska M, u. a. DGU; 2011.

RCC 2011 DGU
Histology, metastases and palliative surgery in mRCC patients. Data from a clinical registry – RCC Registry.

Müller L, Münch A, Goebell PJ, Koska M, Marschner N. Onkologie. 2011;34 (Suppl.6)(P616):182.

RCC 2011 DGHO
Epidemiologisches Register zur Darstellung der Behandlungsrealität und der Therapiemodalitäten beim behandlungsbedürftigen metastasierten oder lokal fortgeschrittenen Nierenzellkarzinom.

Münch A. Sylt; 2011.

RCC 2011 Urolog. Sommerforum (BDU)
Tolerability of different first-line treatment (trt) regimens in patients (pts) with advanced or metastatic renal cell carcinoma (mRCC).

Müller L, Münch A, Blumenstengel K, Hutzschenreuther U, Busies S. J Clin Oncol. 2010;28(Sup. abstr e15086).

RCC 2010 ASCO
Physicians underestimate the severity of fatigue, stomatitis, HFS and dysgeusia in mRCC-patients on systemic therapy: Interimanalysis of the FAtigue, Mucositis, Hand-Foot-Syndrome, and DysgeUSia in RCC study (FAMOUS).

Marschner N, Münch A, Lerchenmüller C, Linz B, Müller L. Onkologie. 2010;33, Sup. 6:58.

RCC 2010 DGHO
Die Behandlungsrealität von Patienten mit metastasiertem Nierenzellkarzinom in Deutschland – das RCC-Register.

Legal W, Münch A, Müller L, Blumenstengel K, Lück A, Hipper A. J Urol Urogynäkol. 2010;17(Sonderheft 3):7.

RCC 2010 J Urol Urogynäkol
Epidemiologisches Register zur Darstellung der Behandlungsrealität und der Therapiemodalitäten beim behandlungsbedürftigen metastasierten oder lokal fortgeschrittenen Nierenzellkarzinom.

Marschner N, Müller L. Berlin; 2010.

RCC 2010 DKK
Impact of adverse drug reactions (ADR) on systemic therapy in patients (pts) with advanced or metastatic renal cell carcinoma (mRCC).

Marschner N, Münch A, Blumenstengel K, Sauer U, Müller L. Ann Oncol. 2010;21 (suppl 8)(Abstract 949):viii298.

RCC 2010 ESMO
Treatment of patients with advanced or metastatic Renal Cell Carcinoma (RCC-Registry): A “Real LIFE” treatment overview of non-trial patients in outpatient cancer centres in Germany.

Müller L, Münch A, Blumenstengel K, Sauer U, Goebell P, Hipper A. Onkologie. 2009;32 (suppl 4):243.

RCC 2009 DGHO
Epidemiologisches Register zur Darstellung der Behandlungsrealität und der Therapiemodalitäten beim behandlungsbedürftigen metastasiertenoder lokal fortgeschrittenen Nierenzellkarzinom.

Köhler. Mannheim; 2009.

RCC 2009 AKS-Studientreffen

Merken

iOMEDICO AG
Hanferstraße 28
D-79108 Freiburg

Phone: 0761 - 15 242 0
E-Mail: info@iomedico.com